Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib to Adjuvant NSAI for HR-positive, HER2-negative EBC at Risk of Recurrence By Ogkologos - October 8, 2025 222 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Akeega, Fixed-Dose Combinations of... March 10, 2023 Qué saber al buscar información sobre el cáncer en línea: perspectiva... August 11, 2022 Commemorating and Making History: The National Cancer Act 50th Anniversary February 8, 2021 It Might Sound Trite But… May 11, 2021 Load more HOT NEWS How to Cope With Panic Attacks During Cancer Celebrating 20 Years of Cancer.Net: How We’ve Worked to Empower People... New Research in Treating Lymphoma and Improving Equity in Cancer Clinical... ¿Las píldoras anticonceptivas afectan mi riesgo de cáncer?
